Scancell Holdings PLC @ Sachs_OIF

Scancell Holdings PLC presentation by Sath Nirmalananthan, CFO
at the 10th Annual Oncology Innovation Forum
Scancell is a clinical stage immunoncology company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer. Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies to redirect immune cells or drugs.
Scancell's lead asset SCIB1, a cancer vaccine being evaluated in first line unresectable metastatic melanoma and has impressive early clinical results as a monotherapy (88% DFS) and in combination with checkpoint inhibitors (85% ORR). The next data is anticipated in Q3 2024.